Codexis (CDXS) Stock Price, News & Analysis

Company Overview

Codexis, Inc. is a biotechnology company that develops enzyme-based technologies and biocatalysts for pharmaceutical, life sciences and industrial applications. Its technology is designed to help customers produce complex molecules more efficiently, with potentially improved selectivity, productivity and sustainability compared with conventional chemical manufacturing methods.

The company’s core technology platform, CodeEvolver, uses protein engineering, data science and laboratory methods to develop enzymes with specific performance characteristics. Codexis provides engineered enzymes and related solutions for applications including the manufacture of active pharmaceutical ingredients, pharmaceutical intermediates, nucleic acid components and other high-value chemicals.

Codexis was founded in 2002 and is headquartered in Redwood City, California. The company works with customers and partners internationally, serving pharmaceutical and other life sciences markets as well as selected industrial and specialty-chemical applications. Its business includes both the development of customized enzyme solutions and the commercialization of enzyme products.

Stephen Dilly serves as Codexis’ president and chief executive officer. The company’s shares trade on the Nasdaq under the symbol CDXS.

Key Stats

• Today's Range: $1.34 to $1.41
• 50-Day Range: $1.32 to $1.70
• 52-Week Range: $0.96 to $2.98
• Volume: 893,224 shs
• Average Volume: 764,706 shs
• Market Capitalization: $152.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.50
• Consensus Rating: Hold

Codexis Stock Analysis - MarketRank™

Codexis scored higher than 37% of companies evaluated by MarketBeat, and ranked 684th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Codexis has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Codexis has a consensus price target of $6.50, representing about 367.6% upside from its current price of $1.39.

Amount of Analyst Coverage

Codexis has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Codexis are expected to grow in the coming year, from ($0.37) to ($0.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Codexis is -4.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Codexis is -4.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Codexis has a P/B Ratio of 2.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.81% of the float of Codexis has been sold short.

Short Interest Ratio / Days to Cover

Codexis has a short interest ratio ("days to cover") of 5.74.

Change versus previous month

Short interest in Codexis has recently increased by 4.59%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Codexis does not currently pay a dividend.

Dividend Growth

Codexis does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for CDXS on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Codexis insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.50% of the stock of Codexis is held by insiders.

Percentage Held by Institutions

78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:CDXS
• CIK: 1200375
• Web: www.codexis.com
• Phone: (650) 421-8100
• Fax: 650-421-8102
• Employees: 146
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Codexis: $6.50
• High Price Target: $8.00
• Low Price Target: $5.00
• Potential Upside/Downside: +367.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$43.97 million
• Net Margins: -39.55%
• Pretax Margin: -39.46%
• Return on Equity: -74.36%
• Return on Assets: -23.58%

Debt

• Debt-to-Equity Ratio: 1.03
• Current Ratio: 3.06
• Quick Ratio: 2.99

Sales & Book Value

• Annual Sales: $70.39 million
• Price / Sales: 2.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.56 per share
• Price / Book: 2.48

Miscellaneous

• Outstanding Shares: 109,510,000
• Free Float: 105,673,000
• Market Cap: $152.22 million
• Optionable: Optionable
• Beta: 2.55